Coetzee, JacorienCronje, StephanieDobrzanska, LilianaRaubenheimer, Helgard G.Joone, Gisela KätheNell, Margo JudithHoppe, Heinrich C.2011-05-052011-05-052011-01Coetzee, J, Cronje, S, Dobrzanska, L, Raubenheimer, HG, Joone, G, Nell, MJ & Hoppe, HC 2011, 'Novel N-heterocyclic ylideneamine gold(I) complexes : synthesis, characterisation and screening for antitumour and antimalarial activity', Dalton Transactions, vol. 40, pp. 1471–1483. [http://www.rsc.org/dalton]1477-9226 (print)1477-9234 (online)10.1039/c0dt01312ahttp://hdl.handle.net/2263/16481Ylideneamine functionalised heterocyclic ligands, 1,3-dimethyl-1,3-dihydro-benzimidazol-2-ylideneamine (I), 3-methyl-3H-benzothiazol-2-ylideneamine (II) or 3,4-dimethyl-3H-thiazol-2-ylideneamine (III), were employed in the preparation of a series of both charged and neutral gold(I) complexes consisting either of a Au(C6F5) fragment (1–3), a [Au(PPh3)]+ unit (4–6) or a [Au(NHC)]+ unit (7) coordinated to the imine nitrogen of the neutral ylideneamine ligand. These complexes were fully characterised by various techniques including X-ray diffraction. In addition, the antitumour and antimalarial potential of selected compounds were assessed in a preliminary study aimed at determining the medicinal value of such compounds. Complexation of the azol-2-ylideneamine ligands with [Au(PPh3)]+ increases their antitumour as well as antimalarial activity.en© The Royal Society of Chemistry 2011.N-heterocyclic ylideneamine gold(I)Anti-infective agents -- South AfricaTumors -- Treatment -- Research -- South AfricaMalaria -- Treatment -- Research -- South AfricaArticle